Posted by Michael Wonder on 29 Oct 2020
PTAC recommends the reimbursement of osimertinib mesylate for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutated non-small cell lung cancer
29 October 2020 - PTAC has acknowledged the high unmet clinical need and the high quality, randomised control trial evidence that reported benefit in progression-free survival compared with the comparator (gefitinib or erlotinib hydrochloride).
The recommendation states that osimertinib mesylate should funded only if cost-neutral to the current first-line pharmaceuticals in this indication.
The PTAC is not convinced that the improvement in progression-free survival will translate to an improvement in overall survival.
